Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.

Why work with us

Solupore enables the manufacture of gene-modified cell therapies with superior cell heath and function. We offer

Automated reproducible transfection: A closed and robust non-viral delivery technology that enables complex editing workflows in cell therapy manufacturing.

Versatile delivery of cargo: Transfection of a broad range of cargo and gene-editing tools, including mRNA, CRISPR/Cas9, and plasmids to T cells and other blood cells.

Full GMP support by 2H 2024: GMP instrument and reagent supported by appropriate regulatory filings.